Navigation Links
SPO Medical Completes Restructuring Plan
Date:2/2/2010

NEW YORK, February 2 /PRNewswire-FirstCall/ -- SPO Medical Inc. (SPOM, http://finance.yahoo.com/q?s=SPOM.OB), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced it has restructured the Company operations to focus primarily on licensing its core technology for non-medical market applications. A restructuring plan has now been completed which involved the reduction of the Company's corporate and manufacturing workforce and a licensing agreement for the existing medical PulseOx product line. Going forward, SPO Medical Inc. will operate as a development and licensing company. These corporate changes were designed to streamline the organization and right-size the G&A and overhead structure.

Under this new structure, the PulseOx medical product line will be marketed by SPO Medical Systems Ltd., a private Israeli company owned and managed by the original founder of SPO Medical, Mr. Israel Sarussi. As per the license agreement, all worldwide sales, marketing and manufacturing of the PulseOx line has been transferred to SPO Medical Systems Ltd. The licensee has retained much of the workforce previously employed by the Company in connection with manufacture and marketing of the PulseOx medical product line. Additional details relating to the license are included in the Company's current report on Form 8-K that was recently filed.

Michael Braunold, President and Chief Executive Officer of SPO Medical Inc. commented: "The licensing of our medical technology and associated PulseOx product line to SPO Medical Systems Ltd. should enable further growth of our medical product offering in the market. As a result, we will be focusing all our corporate efforts on new non-medical product offerings which relate to consumer mass-market opportunities. The licensing agreement and associated restructuring plan should have no impact on the current 200,000 SPO Medical end-users or worldwide reseller network that operates in over 40 countries that will now be serviced by SPO Medical Systems Ltd. - I have every confidence that the existing PulseOx product line will be further enhanced by Mr. Sarussi and his team."

Israel Sarussi, Managing Director of SPO Medical Systems Ltd. commented: "The opportunity now exists for further enhancement of the existing PulseOx product line in addition to expanding the offering by incorporating new medical products and related technologies going forward. We look forward to maintaining the high level of support and commitment to the existing customer base and to the SPO authorized resellers worldwide."

During 2010, SPO Medical Inc. plans to embark on business development activities that will focus on various commercial applications relating to the implementation of reflectance pulse oximetry for non-medical markets. Applications include the consumer sports watch and associated wellness devices, a baby movement monitor and various other mass-market product opportunities that could use pulse oximetry in a non-invasive, convenient manner enabling accurate and effective measurements of vital sign information. Braunold continued; "Commercially, we believe that our unique technology can attract interest from various non-medical corporations who are seeking commercial solutions for mass-market consumer markets; in addition, this strategy should further contribute to potentially increasing value for the SPO shareholders."

About SPO Medical:

SPO Medical (SPOM, http://finance.yahoo.com/q?s=SPOM.OB) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spomedical.com and http://www.spobaby.com.

Forward Looking Statements:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, our ability to raise funds, sufficiency of working capital resources, patent protection for our products and technologies, market acceptance of our products and new product applications, product performance, size of prospective markets, revenues assessments, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the sufficiency and availability of working capital, the introduction of competing products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2008. We undertake no obligation to revise or update any forward-looking statement for any reason.

    SPO Medical Contact:
    Michael Braunold, Chief Executive Officer.
    investors@spomedical.com
    +972-54-695-9504


SOURCE SPO Medical Inc.


'/>"/>
SOURCE SPO Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... /PRNewswire/--  Cell Applications, Inc. and Cyfuse Biomedical ... now available in North America ... approach called the "Kenzan Method." Utilizing Cyfuse Biomedical,s ... robotic system that fabricates 3D tissue from cells, ... model that makes scaffold-free tissue available immediately to ...
(Date:2/8/2016)... Velano Vascular, a medical technology company transforming ... their practitioners, announced today that the company has raised ... the proceeds from this financing, an extension of a ... to support the development and commercialization of the company,s ... Philadelphia , and a number ...
(Date:2/8/2016)... 2016  Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS ... delivery systems, today announced that it will release its financial ... 2015 after market close on February 9, 2016.  At this ... discuss these financial results.    About Unilife Corporation ... About Unilife Corporation UNIS ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its affiliated companies ... Gary D. Radine, who recently retired as president and CEO of Delta Dental of ... CEO of the Year , helped lead the effort to raise funds for studies ...
(Date:2/8/2016)... ... 08, 2016 , ... Eating disorders and post-traumatic stress disorder ... and men with eating disorders report a history of trauma, research suggests that ... an eating disorder. , At the 2016 iaedp Symposium, the workshop, “What ...
(Date:2/8/2016)... ... 08, 2016 , ... GrassrootsHealth published data from its D*action ... diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than a ... health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of ...
(Date:2/8/2016)... Vegas, Nevada (PRWEB) , ... February 08, 2016 ... ... at RowdMap, Inc., will be speaking on how healthcare companies can use newly ... costs, manage the health of a population and intervene and capture the value ...
(Date:2/8/2016)... ... 2016 , ... According to research by the National Association ... to be certified or obtain continuing education. To increase patient awareness of the ... Mouth?” campaign to inform dentists and patients about the possible lack of skills ...
Breaking Medicine News(10 mins):